title: [The effect of inhibitory and activating natural killer cell immunoglobulin receptor on haplo-identical hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To investigate the effect of inhibitory and activating KIRs on a cohort of Chinese leukemia patients who received haplo-identical hematopoietic stem cell transplantation (HSCT).
  
  
  METHODS
  Donor's inhibitory and activating KIRs and recipient's HLA-C from 47 cases who received haplo-identical HSCT were tested by PCR-SSP. 2 year overall survival (OS), incidence of severe (grade III to IV) acute GVHD (aGVHD) and relapse rate (RR) were analyzed.
  
  
  RESULTS
  (1) According to Matched (M) vs Mis-Matched (MM) between donor's inhibitory KIR and recipient's HLA-C1/C2 subgroup, 2 year OS rate in M group [(87.5 +/- 8.3)%] was significantly higher than that in MM group (54.5 +/- 9.0)%, (P = 0.03). Lower incidence of relapse rate was seen in M group than in M/MM groups [0 vs (25.4 +/- 9.5)%, P = 0.05]. In 30 cases of myeloid leukemia patients, there was lower RR in M group than in MM groups [0 vs (35.0 +/- 14.4)%, P = 0.04]. (2) According to the 3 activating KIR genes: KIR2DS1/ KIR2DS2/ KIR2DS3, lower incidence of grade III-IV aGVHD was seen in KIR2DS1 (+) group than in KIR2DS1 (-) group (13% vs 28%, respectively, P > 0.05); and so was done in KIR2DS3 (+) group (11% vs 26%, respectively, P > 0.05). The RR was lower in KIR2DS2 (+) group [0% vs (17.3 +/- 7.1)%, respectively, P > 0.05].
  
  
  CONCLUSIONS
  In our haplo-identical HSCT setting, match between donor's inhibitory KIR and recipient's HLA-C can significantly reduce the incidence of relapse rate and improve OS. Although lower incidences of severe aGVHD are noted in the donors with KIR2DS1 (+) or KIR2DS3 (+), and lower relapse rate is noted in the donors with KIR2DS2 (+) but without statistic difference, no remarkable effects of activating KIRs on OS have been found in our relatively small clinical series.
authors.affiliation: Beijing Daopei Hospital, Beijing 100049, China.
authors.forename: Xian
authors.initials: X
authors.lastname: Zhang
authors.forename: Yan-Ling
authors.initials: YL
authors.lastname: Zhang
authors.forename: Jian-Ling
authors.initials: JL
authors.lastname: Wang
authors.forename: Chun-Rong
authors.initials: CR
authors.lastname: Tong
authors.forename: Peng
authors.initials: P
authors.lastname: Cai
authors.forename: Hong-Xing
authors.initials: HX
authors.lastname: Liu
authors.forename: Jing-Bo
authors.initials: JB
authors.lastname: Wang
authors.forename: Xing-Yu
authors.initials: XY
authors.lastname: Cao
authors.forename: Yu-Ming
authors.initials: YM
authors.lastname: Ying
authors.forename: Tong
authors.initials: T
authors.lastname: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D005838:Genotype; D006086:Graft vs Host Disease; D015236:HLA-C Antigens / Q000235:genetics*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D054340:Receptors, KIR / Q000145:classification; D012008:Recurrence; D035781:Siblings; D015996:Survival Rate; D014019:Tissue Donors; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D015236:HLA-C Antigens; D054340:Receptors, KIR